Ginkgo Bioworks Holdings, Inc. (DNA)
Pre-market:
| Previous close | 0.8390 |
| Open | 0.8400 |
| Bid | 0.8130 x 2900 |
| Ask | 0.0000 x 1100 |
| Day's range | 0.7890 - 0.8694 |
| 52-week range | 0.7200 - 2.5450 |
| Volume | |
| Avg. volume | 36,176,269 |
| Market cap | 1.781B |
| Beta (5Y monthly) | 1.42 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4300 |
| Earnings date | 01 Mar 2024 - 05 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.43 |
PR NewswireGinkgo Bioworks to Participate in Two Conferences in May
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that management will be participating in two investor conferences in May.
- PR Newswire
Sojitz Corporation and Ginkgo Bioworks Announce Plans to Use Synthetic Biology R&D Services to Accelerate Sustainable Manufacturing in Japan
Sojitz, a large Japanese general trading company with extensive networks within the Japanese bioeconomy, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a binding definitive agreement. Together, Sojitz and Ginkgo aim to build connections with key Japanese businesses and encourage the use of synthetic biology to develop sustainable production processes.
- PR Newswire
Ginkgo Bioworks Receives Continued Listing Standard Notice From NYSE
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and biosecurity, today announced that it received a notice on May 7, 2024 from the New York Stock Exchange ("NYSE") informing the Company that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company's Class A common stock was less than $1 per share over a consecutive 30 trading-day period. The no
